The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage

Pilar Ciruela; Conchita Izquierdo; Sonia Broner; Carmen Muñoz-Almagro; Sergi Hernández; Carmen Ardanuy; Roman Pallarés; Angela Domínguez; Mireia Jané; Cristina Esteva; Mariona Fernández de Sevilla; Desiree Henares; Immaculada Grau; Francesc Marco; Jaume Llaberia; Araceli González-Cuevas; Alvaro Díaz; Maria Teresa Martin; Montserrat Sierra; Margarida Curriu; Carme Gallés; Pilar Hernández; Paula Gassiot; Matilde Martínez-Zurita; Carmina Martí; Montserrat Morta; Goretti Sauca; Asunción Gassós; Esther Sanfeliu; Frederic Ballester; Isabel Pujol; Montserrat Olsina; Xavier Raga; Frederic Gómez-Bertomeu; Mar Olga Pérez-Moreno; Anna Vilamala; Marian Navarro; Mercè Ribelles; Eduardo Padilla; Nuria Prim; Dionisia Fontanals; Miguel Angel Benítez; Eulalia Jou; Carmina Sanjosé; Montserrat Giménez; Maria Dolores Quesada; Jose Carlos de la Fuente; Ana Calderon; Percy Juan Ayala; Laia Vega; Josefa Pérez-Jové; Conchita Balado; Ines Valle

doi:10.1016/j.vaccine.2018.05.026

The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage

Pilar Ciruela, Conchita Izquierdo, Sonia Broner, Carmen Muñoz-Almagro, Sergi Hernández, Carmen Ardanuy, Roman Pallarés, Angela Domínguez, Mireia Jané, Cristina Esteva, Mariona Fernández de Sevilla, Desiree Henares, Immaculada Grau, Francesc Marco, Jaume Llaberia, Araceli González-Cuevas, Alvaro Díaz, Maria Teresa Martin, Montserrat Sierra, Margarida CurriuCarme Gallés, Pilar Hernández, Paula Gassiot, Matilde Martínez-Zurita, Carmina Martí, Montserrat Morta, Goretti Sauca, Asunción Gassós, Esther Sanfeliu, Frederic Ballester, Isabel Pujol, Montserrat Olsina, Xavier Raga, Frederic Gómez-Bertomeu, Mar Olga Pérez-Moreno, Anna Vilamala, Marian Navarro, Mercè Ribelles, Eduardo Padilla, Nuria Prim, Dionisia Fontanals, Miguel Angel Benítez, Eulalia Jou, Carmina Sanjosé, Montserrat Giménez, Maria Dolores Quesada, Jose Carlos de la Fuente, Ana Calderon, Percy Juan Ayala, Laia Vega, Josefa Pérez-Jové, Conchita Balado, Ines Valle

Research output: Contribution to journal › Article › Research

33 Citations (Scopus)

Abstract

© 2018 Elsevier Ltd Background: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). Methods: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006–2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006–2009) and PCV13 periods (2010–2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2–4 years, 5–64 years and ≥65 years. Results: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2–4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2–4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2–4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. Conclusions: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.

Original language	English
Pages (from-to)	7744-7752
Journal	Vaccine
Volume	36
DOIs	https://doi.org/10.1016/j.vaccine.2018.05.026
Publication status	Published - 29 Nov 2018

Keywords

Impact
IPD
PCV13
PCV7
Serotype distribution
Streptococcus pneumoniae
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2018.05.026

Cite this

Ciruela, P., Izquierdo, C., Broner, S., Muñoz-Almagro, C., Hernández, S., Ardanuy, C., Pallarés, R., Domínguez, A., Jané, M., Esteva, C., de Sevilla, M. F., Henares, D., Grau, I., Marco, F., Llaberia, J., González-Cuevas, A., Díaz, A., Martin, M. T., Sierra, M., ... Valle, I. (2018). The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine, 36, 7744-7752. https://doi.org/10.1016/j.vaccine.2018.05.026

@article{e178fbc583bb4fe3bb95859e7674bfa4,

title = "The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage",

abstract = "{\textcopyright} 2018 Elsevier Ltd Background: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). Methods: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006–2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006–2009) and PCV13 periods (2010–2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2–4 years, 5–64 years and ≥65 years. Results: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2–4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2–4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2–4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. Conclusions: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.",

keywords = "Impact, IPD, PCV13, PCV7, Serotype distribution, Streptococcus pneumoniae, Vaccine",

author = "Pilar Ciruela and Conchita Izquierdo and Sonia Broner and Carmen Mu{\~n}oz-Almagro and Sergi Hern{\'a}ndez and Carmen Ardanuy and Roman Pallar{\'e}s and Angela Dom{\'i}nguez and Mireia Jan{\'e} and Cristina Esteva and {de Sevilla}, {Mariona Fern{\'a}ndez} and Desiree Henares and Immaculada Grau and Francesc Marco and Jaume Llaberia and Araceli Gonz{\'a}lez-Cuevas and Alvaro D{\'i}az and Martin, {Maria Teresa} and Montserrat Sierra and Margarida Curriu and Carme Gall{\'e}s and Pilar Hern{\'a}ndez and Paula Gassiot and Matilde Mart{\'i}nez-Zurita and Carmina Mart{\'i} and Montserrat Morta and Goretti Sauca and Asunci{\'o}n Gass{\'o}s and Esther Sanfeliu and Frederic Ballester and Isabel Pujol and Montserrat Olsina and Xavier Raga and Frederic G{\'o}mez-Bertomeu and P{\'e}rez-Moreno, {Mar Olga} and Anna Vilamala and Marian Navarro and Merc{\`e} Ribelles and Eduardo Padilla and Nuria Prim and Dionisia Fontanals and Ben{\'i}tez, {Miguel Angel} and Eulalia Jou and Carmina Sanjos{\'e} and Montserrat Gim{\'e}nez and Quesada, {Maria Dolores} and {de la Fuente}, {Jose Carlos} and Ana Calderon and Ayala, {Percy Juan} and Laia Vega and Josefa P{\'e}rez-Jov{\'e} and Conchita Balado and Ines Valle",

year = "2018",

month = nov,

day = "29",

doi = "10.1016/j.vaccine.2018.05.026",

language = "English",

volume = "36",

pages = "7744--7752",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

}

Ciruela, P, Izquierdo, C, Broner, S, Muñoz-Almagro, C, Hernández, S, Ardanuy, C, Pallarés, R, Domínguez, A, Jané, M, Esteva, C, de Sevilla, MF, Henares, D, Grau, I, Marco, F, Llaberia, J, González-Cuevas, A, Díaz, A, Martin, MT, Sierra, M, Curriu, M, Gallés, C, Hernández, P, Gassiot, P, Martínez-Zurita, M, Martí, C, Morta, M, Sauca, G, Gassós, A, Sanfeliu, E, Ballester, F, Pujol, I, Olsina, M, Raga, X, Gómez-Bertomeu, F, Pérez-Moreno, MO, Vilamala, A, Navarro, M, Ribelles, M, Padilla, E, Prim, N, Fontanals, D, Benítez, MA, Jou, E, Sanjosé, C, Giménez, M, Quesada, MD, de la Fuente, JC, Calderon, A, Ayala, PJ, Vega, L, Pérez-Jové, J, Balado, C & Valle, I 2018, 'The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage', Vaccine, vol. 36, pp. 7744-7752. https://doi.org/10.1016/j.vaccine.2018.05.026

TY - JOUR

T1 - The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage

AU - Ciruela, Pilar

AU - Izquierdo, Conchita

AU - Broner, Sonia

AU - Muñoz-Almagro, Carmen

AU - Hernández, Sergi

AU - Ardanuy, Carmen

AU - Pallarés, Roman

AU - Domínguez, Angela

AU - Jané, Mireia

AU - Esteva, Cristina

AU - de Sevilla, Mariona Fernández

AU - Henares, Desiree

AU - Grau, Immaculada

AU - Marco, Francesc

AU - Llaberia, Jaume

AU - González-Cuevas, Araceli

AU - Díaz, Alvaro

AU - Martin, Maria Teresa

AU - Sierra, Montserrat

AU - Curriu, Margarida

AU - Gallés, Carme

AU - Hernández, Pilar

AU - Gassiot, Paula

AU - Martínez-Zurita, Matilde

AU - Martí, Carmina

AU - Morta, Montserrat

AU - Sauca, Goretti

AU - Gassós, Asunción

AU - Sanfeliu, Esther

AU - Ballester, Frederic

AU - Pujol, Isabel

AU - Olsina, Montserrat

AU - Raga, Xavier

AU - Gómez-Bertomeu, Frederic

AU - Pérez-Moreno, Mar Olga

AU - Vilamala, Anna

AU - Navarro, Marian

AU - Ribelles, Mercè

AU - Padilla, Eduardo

AU - Prim, Nuria

AU - Fontanals, Dionisia

AU - Benítez, Miguel Angel

AU - Jou, Eulalia

AU - Sanjosé, Carmina

AU - Giménez, Montserrat

AU - Quesada, Maria Dolores

AU - de la Fuente, Jose Carlos

AU - Calderon, Ana

AU - Ayala, Percy Juan

AU - Vega, Laia

AU - Pérez-Jové, Josefa

AU - Balado, Conchita

AU - Valle, Ines

PY - 2018/11/29

Y1 - 2018/11/29

N2 - © 2018 Elsevier Ltd Background: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). Methods: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006–2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006–2009) and PCV13 periods (2010–2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2–4 years, 5–64 years and ≥65 years. Results: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2–4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2–4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2–4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. Conclusions: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.

AB - © 2018 Elsevier Ltd Background: We studied the impact of 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of invasive pneumococcal disease (IPD) and serotype distribution in a region with intermediate levels of vaccination (around 64% in children aged <2 years). Methods: Surveillance data on IPD cases reported by microbiologists participating in the Microbiological Reporting System of Catalonia during 2006–2014 were analysed. We compared estimated incidence rate (IR) ratios for serotypes included in PCV7, PCV10non7, PCV13non10 and non-PCV13 between the PCV7 (2006–2009) and PCV13 periods (2010–2014). IR were corrected for missing serotypes according to year and age groups: <2 years, 2–4 years, 5–64 years and ≥65 years. Results: A total of 9338 IPD cases were reported. Overall IPD incidence declined by 26.2% (from 16.4 to 12.1) in the PCV13 period. The largest decrease was observed in children aged 2–4 years (44.5%, from 37.4 to 20.8). Pneumonia fell in all age groups with the largest reduction in children aged 2–4 years (49.3%) and <2 years (42%). PCV13 serotypes decreased significantly in all age groups, from 52% (31.6 to 15.1) in children aged 2–4 years to 35% (22.8 to 14.8) in adults aged ≥65 years. Non-PCV13 serotypes rose by 13% (14.8 to 16.8) in people aged ≥65 years. Conclusions: In a region with intermediate vaccination coverage, the introduction of PCV13 has reduced the overall incidence of IPD, mainly due to the decrease in PCV13 serotypes in all age groups, suggesting herd immunity. Non-PCV13 serotypes have increased in adults aged ≥65 years, suggesting serotype replacement. Higher PCV13 vaccination coverage in children will further reduce IPD incidence in all age groups.

KW - Impact

KW - IPD

KW - PCV13

KW - PCV7

KW - Serotype distribution

KW - Streptococcus pneumoniae

KW - Vaccine

U2 - 10.1016/j.vaccine.2018.05.026

DO - 10.1016/j.vaccine.2018.05.026

M3 - Article

SN - 0264-410X

VL - 36

SP - 7744

EP - 7752

JO - Vaccine

JF - Vaccine

ER -

The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this